MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

by Rafael eDe La Torre, Samanta eYubero-Lahoz, Ricardo ePardo-Lozano, Magi eFarre
Published 2012-11-01

Semantic verbal fluency pattern, dementia rating scores and adaptive behavior correlate with plasma Aβ42 concentrations in Down syndrome young adults

by Laura eDel Hoyo, Laura eDel Hoyo, Laura eXicota, Laura eXicota, Laura eXicota, Gonzalo eSánchez, Aida M Cuenca, Susana ede Sola, Susana ede Sola, Klaus eLangohr, Klaus eLangohr, Ana B Fagundo, Ana B Fagundo, Magi eFarre, Magi eFarre, Mara eDierssen, Mara eDierssen, Mara eDierssen, Rafael eDe La Torre, Rafael eDe La Torre, Rafael eDe La Torre
Published 2015-11-01

Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the Spanish Society of Clinical Pharmacology.

by José A.G. eAgúndez, Jaime edel Barrio, Teresa ePadró, Camilla eStephens, Magí eFarré, Raúl J Andrade, Lina eBadimon, Elena eGarcía-Martín, Gemma eVilahur, M Isabel eLucena
Published 2012-01-01

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

by Susana ede Sola, Susana ede Sola, Rafael ede la Torre, Rafael ede la Torre, Rafael ede la Torre, Gonzalo eSanchez-Benavides, Gonzalo eSanchez-Benavides, Bessy eBenejam, Aida eCuenca-Royo, Aida eCuenca-Royo, Laura edel Hoyo, Joan eRodriguez, Silvina eCatuara-Solarz, Judit eSanchez-Gutiérrez, Ivan eDueñas-Espin, Ivan eDueñas-Espin, Gimena eHernandez, Gimena eHernandez, Jordi ePeña-Casanova, Jordi ePeña-Casanova, Klaus eLangohr, Klaus eLangohr, Sebastià eVidela, Henri eBléhaut, Magi eFarré, Magi eFarré, Mara eDierssen, Mara eDierssen, the eTESDAD Study Group
Published 2015-06-01